Su Jung Han1, Tae Hoon Lee2, Byong Il Kang1, Hyun Jong Choi3, Yun Nah Lee3, Sang-Woo Cha4, Jong Ho Moon3, Young Deok Cho4, Sang Hum Park1, Sun-Joo Kim1. 1. Division of Gastroenterology, Department of Internal Medicine, Cheonan Hospital, Soonchunhyang University College of Medicine, 23-20 Bongmyung-Dong, Cheonan, Choongnam, 330-721, Republic of Korea. 2. Division of Gastroenterology, Department of Internal Medicine, Cheonan Hospital, Soonchunhyang University College of Medicine, 23-20 Bongmyung-Dong, Cheonan, Choongnam, 330-721, Republic of Korea. thlee9@schmc.ac.kr. 3. Division of Gastroenterology, Department of Internal Medicine, Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Wonmi-gu, Bucheon, 14584, Republic of Korea. 4. Division of Gastroenterology, Department of Internal Medicine, Seoul Hospital, Soonchunhyang University College of Medicine, 59, Daesagwan-ro, Yongsan-gu, Seoul, 140-887, Republic of Korea.
Abstract
BACKGROUND/AIMS: Concern regarding the safety and efficacy of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in elderly patients is increasing as a result of the aging society. However, there are limited data, especially in the super-aged elderly. This study aimed to evaluate the efficacy and safety of therapeutic ERCP in patients ≥80 years of age. METHODS: Patients 80 years of age or older (n = 312) and younger than 65 years (n = 312) who underwent therapeutic ERCP from June 2006 to April 2014 were randomly selected and analyzed retrospectively. The main outcome measurements were therapeutic ERCP-related complications and clinical outcomes in the two groups. RESULTS: Choledocholithiasis combined with gallbladder stone was the most common indication for ERCP in both groups. Comorbid diseases (70.5 and 29.8 %, p < 0.001) and the use of anti-thrombotic drugs (18.6 and 1.6 %, p < 0.001) were more frequent in the super-aged group. The mean procedure time was longer, and the frequency of second ERCP was more common in the super-aged group. However, the technical success rate (94.9 and 97.4 %, p = 0.096) and the procedure-related complication rate (4.8 and 5.8 %, p = 0.592) were not different between the two groups. Post-ERCP pancreatitis occurred in 1.3 % of the super-aged group and in 2.9 % of the control group (p = 0.262). Cardiopulmonary complications occurred in 1.9 % of patients in each group (p = 1.0). CONCLUSIONS: Therapeutic ERCP is comparable in terms of efficacy and safety between patients ≥80 years and those <65 years of age, although the elderly group had a higher rate of comorbid diseases and used anti-thrombotic drugs more frequently.
BACKGROUND/AIMS: Concern regarding the safety and efficacy of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in elderly patients is increasing as a result of the aging society. However, there are limited data, especially in the super-aged elderly. This study aimed to evaluate the efficacy and safety of therapeutic ERCP in patients ≥80 years of age. METHODS:Patients 80 years of age or older (n = 312) and younger than 65 years (n = 312) who underwent therapeutic ERCP from June 2006 to April 2014 were randomly selected and analyzed retrospectively. The main outcome measurements were therapeutic ERCP-related complications and clinical outcomes in the two groups. RESULTS:Choledocholithiasis combined with gallbladder stone was the most common indication for ERCP in both groups. Comorbid diseases (70.5 and 29.8 %, p < 0.001) and the use of anti-thrombotic drugs (18.6 and 1.6 %, p < 0.001) were more frequent in the super-aged group. The mean procedure time was longer, and the frequency of second ERCP was more common in the super-aged group. However, the technical success rate (94.9 and 97.4 %, p = 0.096) and the procedure-related complication rate (4.8 and 5.8 %, p = 0.592) were not different between the two groups. Post-ERCP pancreatitis occurred in 1.3 % of the super-aged group and in 2.9 % of the control group (p = 0.262). Cardiopulmonary complications occurred in 1.9 % of patients in each group (p = 1.0). CONCLUSIONS: Therapeutic ERCP is comparable in terms of efficacy and safety between patients ≥80 years and those <65 years of age, although the elderly group had a higher rate of comorbid diseases and used anti-thrombotic drugs more frequently.
Authors: E Masci; G Toti; A Mariani; S Curioni; A Lomazzi; M Dinelli; G Minoli; C Crosta; U Comin; A Fertitta; A Prada; G R Passoni; P A Testoni Journal: Am J Gastroenterol Date: 2001-02 Impact factor: 10.864
Authors: C Boustière; A Veitch; G Vanbiervliet; P Bulois; P Deprez; A Laquiere; R Laugier; G Lesur; P Mosler; B Nalet; B Napoleon; B Rembacken; N Ajzenberg; J P Collet; T Baron; J-M Dumonceau Journal: Endoscopy Date: 2011-05-04 Impact factor: 10.093
Authors: Jang Eon Kim; Byung Hyo Cha; Sang Hyub Lee; Young Soo Park; Jin-Wook Kim; Sook-Hyang Jeong; Na Young Kim; Dong Ho Lee; Jin-Hyeok Hwang Journal: Korean J Gastroenterol Date: 2011-04
Authors: Peter B Cotton; Glenn M Eisen; Lars Aabakken; Todd H Baron; Matt M Hutter; Brian C Jacobson; Klaus Mergener; Albert Nemcek; Bret T Petersen; John L Petrini; Irving M Pike; Linda Rabeneck; Joseph Romagnuolo; John J Vargo Journal: Gastrointest Endosc Date: 2010-03 Impact factor: 9.427
Authors: Marianna Galeazzi; Paolo Mazzola; Breanna Valcarcel; Giuseppe Bellelli; Marco Dinelli; Giulio Maria Pasinetti; Giorgio Annoni Journal: BMC Gastroenterol Date: 2018-03-14 Impact factor: 3.067
Authors: Ahmad Hormati; Reza Aminnejad; Mohammad Saeidi; Mohammad Reza Ghadir; Abolfazl Mohammadbeigi; Hamed Shafiee Journal: Anesth Pain Med Date: 2019-08-26